Original Article

European Journal of Nuclear Medicine and Molecular Imaging

, Volume 38, Issue 1, pp 46-52

First online:

18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer

  • Ashley M. GrovesAffiliated withInstitute of Nuclear Medicine, University College London Email author 
  • , Manu ShastryAffiliated withInstitute of Nuclear Medicine, University College London
  • , Manuel Rodriguez-JustoAffiliated withDepartment of Histopathology, University College London
  • , Anmol MalhotraAffiliated withBreast Unit, Royal Free Hospital, UCL
  • , Raymondo EndozoAffiliated withInstitute of Nuclear Medicine, University College London
  • , Timothy DavidsonAffiliated withBreast Unit, Royal Free Hospital, UCL
  • , Tina KelleherAffiliated withBreast Unit, Royal Free Hospital, UCL
  • , Kenneth A. MilesAffiliated withBrighton and Sussex University Hospitals
  • , Peter J. EllAffiliated withInstitute of Nuclear Medicine, University College London
    • , Mohammed R. KeshtgarAffiliated withBreast Unit, Royal Free Hospital, UCL

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose

Tumour angiogenesis is an independent and strong prognostic factor in early breast carcinoma. We performed this study to investigate the ability of 18F-FDG to detect angiogenesis in early breast carcinoma using PET/CT.

Methods

Twenty consecutive patients with early (T1-T2) breast carcinoma were recruited prospectively for 18F-FDG PET/CT. The PET/CT data were used to calculate whole tumour maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean). All patients underwent subsequent surgery without prior chemotherapy or radiotherapy. The excised tumour underwent immunohistochemistry for vascular endothelial growth factor (VEGF), CD105 and glucose transporter protein 1 (GLUT1).

Results

The SUVmax showed the following correlation with tumour histology: CD105: r = 0.60, p = 0.005; GLUT1: r = 0.21, p = 0.373; VEGF: r = −0.16, p = 0.496. The SUVmean showed the following correlation with tumour histology: CD105: r = 0.65, p = 0.002; GLUT1: r = 0.34, p = 0.144; VEGF: r = −0.18, p = 0.443

Conclusion

18F-FDG uptake is highly significantly associated with angiogenesis as measured by the immunohistochemistry with CD105 for new vessel formation. Given that tumour angiogenesis is an important prognostic indicator and a predictor of treatment response, 18F-FDG PET may have a role in the management of primary breast cancer patients even in early-stage disease.

Keywords

Angiogenesis Breast cancer Positron emission tomography